Prevention of migraine with olmesartan in patients with hypertension/prehypertension
Prevention of migraine with olmesartan in patients with hypertension/prehypertension
复制标题
DOI：
10.1111/j.1526-4610.2006.00382.x
复制
发表时间：
2006-03-01
期刊：
影响因子：
5
通讯作者：
Byrd, LH
中科院分区：
文献类型：
--
作者：
Charles, JA;Jotkowitz, S;Byrd, LH
客观。-探讨奥美沙坦对高血压和高血压前期共病患者偏头痛发作频率和严重程度的影响。一项随机、双盲、安慰剂对照、交叉研究，共纳入60例患者，证实了血管紧张素II受体阻滞剂坎地沙坦预防偏头痛的有效性和安全性。我们研究了奥美沙坦在预防高血压和高血压前期患者偏头痛方面的潜在疗效和耐受性。24名年龄在27岁至76岁之间的高血压或高血压前期的成年人被纳入这项开放标签研究。参与者患有偏头痛（根据国际头痛协会分类诊断）至少3个月。患者在至少3个月的不同观察期接受10 - 40 mg奥美沙坦治疗。频率和严重程度记录的办公室访问或通过电话采访。患者报告偏头痛发作频率平均降低82.5%。患者的偏头痛发作严重程度平均降低了45%，以1至10的数字疼痛量表测量。唯一的不良反应是头晕或先兆晕厥。未发生严重不良事件，也未发生导致提前终止的不良事件。两名患者的头痛频率、强度和血压没有降低。在高血压或高血压前期患者中进行的这项开放性偏头痛预防研究的有利结果和低不良反应率与在服用坎地沙坦的患者中进行的随机、双盲、安慰剂对照、交叉研究的结果相似。奥美沙坦显示出作为一种有效且耐受性良好的偏头痛预防剂用于高血压和高血压前期共病患者的潜力。
Objective.-To explore the effects of olmesartan on frequency and severity of migraine attacks in patients with comorbid hypertension and prehypertension.Background.-A randomized, double-blind, placebo-controlled, crossover study with a total of 60 patients has demonstrated the efficacy and safety of the angiotensin II receptor blocker candesartan in migraine prophylaxis. We study the potential efficacy and tolerability of olmesartan in preventing migraine in patients with hypertension and prehypertension.Design/Methods.-Twenty-four adults, aged 27 through 76, with either hypertension or prehypertension, were included in this open-label study. Participants suffered from migraines (diagnosed according to International Headache Society classifications) for at least 3 months. Patients were treated with 10 to 40 mg of olmesartan per various observational periods of at least 3 months. Frequency and severity were recorded by office visits or by telephonic interview.Results.-Patients reported an 82.5% average reduction in the frequency of migraine attacks. Patients also experienced a 45% average reduction in the severity of migraine attacks measured on a numeric pain scale of 1 to 10. The only undesired effect was dizziness or presyncope. No serious adverse events occurred and no adverse event caused a premature termination. Two patients had no reduction in headache frequency, intensity, and blood pressure.Conclusions.-The favorable results and low rate of adverse effects, in this open migraine prevention study in patients with hypertension or prehypertension, are similar to results of the randomized, double-blind, placebo-controlled, crossover study in patients taking candesartan. Olmesartan shows a potential as an effective and well-tolerated migraine prophylactic agent for patients with comorbid hypertension and prehypertension.